# Dupilumab_Metastatic NSCLC

> **NCT05013450** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Marron** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** PD-1/PD-L1 blockade
- **DRUG:** Anakinra

## Key facts

- **NCT ID:** NCT05013450
- **Lead sponsor:** Thomas Marron
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-10
- **Primary completion:** 2025-09-10
- **Final completion:** 2025-12-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013450, "Dupilumab_Metastatic NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05013450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*